Emerging therapeutic targets in the short QT syndrome.

Abstract excerpt

INTRODUCTION: Short QT Syndrome (SQTS) is a rare but dangerous condition characterised by abbreviated repolarisation, atrial and ventricular arrhythmias and risk of sudden death. Implantable cardioverter defibrillators (ICDs) are a first line protection against sudden death, but adjunct pharmacology is beneficial and desirable. Areas covered: The genetic basis for genotyped SQTS variants (SQT1-SQT8) and evidence...

Topics

Join the communities discussing this publication.

• Anti-Arrhythmia Agents
• Arrhythmias, Cardiac
• Drug Design
• Genotype
• Molecular Targeted Therapy